Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Collaboration Agreement to provide Metabolomic Profiling Services

Published: Wednesday, March 05, 2014
Last Updated: Wednesday, March 05, 2014
Bookmark and Share
Metabolon Inc will assist Human Longevity Inc to build the world’s largest and most complete human genotype, microbiome and phenotype database.

Metabolon, Inc. announces the signing of an agreement with newly-launched Human Longevity Inc., whereby Metabolon will provide biochemical profiling services to assist HLI in its mission to tackle diseases of aging by building the world’s largest and most complete human genotype, microbiome and phenotype database. In the initial term of the agreement Metabolon will carry out small molecule analysis of 10,000 subjects and collaborate with HLI to map changes in the small molecules to end points of disease and gene mutations.
“We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company. It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”
HLI cofounders are J. Craig Venter, Ph.D., Robert Hariri, M.D., Ph.D. and Peter H. Diamandis, M.D. Dr. Venter, who is well known for leading Celera to the successful sequencing of the human genome, has been a member of Metabolon’s Scientific Advisory Board since 2003.
Under the agreement Metabolon will apply its leading metabolomics technology to augment the genetic and microbiome information HLI is collecting. Metabolon’s metabolomic approach identifies the full complement of metabolites present in a human biological specimen. Metabolomics is important because quantifying and understanding the full picture of circulating biochemicals in the body can help researchers get a clearer picture of that individual’s health status, and provide markers and pathways associated with disease and drug action. In addition, Metabolon will collaborate with HLI to identify small molecule biomarkers of disease, which Metabolon may then use to develop small molecule diagnostic tests.
Commenting on the agreement Dr. Venter said, “The establishment of HLI is the next step beyond the sequencing of the human genome, and may at last provide useful clinical information for the treatment of disease that was lacking from genome mapping alone. Metabolon is a visionary and leader in the field of metabolomics, and I have great confidence in the company’s technology and ability to add significant value to HLI. Because of my position as a member of Metabolon’s Scientific Advisory Board, I have a deep personal appreciation of the company’s impressive methods and scientific expertise.”
John Ryals, Ph.D., Metabolon’s chief executive officer, said, “We are delighted to be aligned with HLI and the world-renowned scientific minds behind this new company. It is thrilling to have the opportunity to make key contributions to the study of aging and we look forward to realizing the benefits of discovery.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Quantose IR™ Measures Insulin Sensitivity Better
Results were recently published online by the Journal of Clinical Endocrinology & Metabolism.
Wednesday, April 01, 2015
Metabolon, Baylor Partner to Screen for Inborn Errors of Metabolism
The two-year, exclusive agreement will provide global Metabolomic-Assisted Pathway Screening (MAPS) services for individuals with suspected inborn errors of metabolism (IEMs).
Thursday, September 04, 2014
Metabolon, Geisinger Partner on Prediabetes Study
Metabolon will sponsor a pilot study to evaluate its Quantose IRTM test as a monitor of glycemic control in people with prediabetes.
Friday, June 27, 2014
New Study Reveals Interplay between Genetics and Metabolism in Complex Disease
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments.
Saturday, May 17, 2014
Interplay between Genetics and Metabolism in Complex Disease Revealed
Metabolomic profiling coupled with genomics data yields new insight into diseases, potential biomarkers and drug treatments
Friday, May 16, 2014
Metabolon Enters into Collaboration with GSK
Agreement will see Metabolon provide metabolomic profiling services to GlaxoSmithKline.
Wednesday, May 14, 2014
Metabolon Debuts New Client Portal at Bio-IT World Expo
MetaboLync™ is a cloud-based solution for sharing, visualizing, and analyzing metabolomics data.
Wednesday, April 30, 2014
Microbes and Metabolites Fuel an Ambitious Aging Project
Craig Venter’s new company wants to improve human longevity by creating the world’s largest, most comprehensive database of genetic and physiological information.
Wednesday, March 12, 2014
Metabolon Closes $15 Million Series E Financing
Company raises $15 million through the issuance of preferred stock.
Monday, January 06, 2014
Global Genomics Group and Metabolon to Collaborate
Metabolon will conduct biochemical profiling in single largest prospective pan-omic study.
Thursday, November 14, 2013
Metabolon and Bostwick Laboratories Announce Marketing Agreement
Under the Agreement Bostwick will market Prostarix™, a non-invasive urine test for stratifying prostate cancer risk.
Monday, November 04, 2013
Metabolon Announces Findings from Two Major Diabetes Outcomes Studies
This provides further evidence that the Quantose test identifies individuals at risk for type 2 diabetes earlier and more accurately than traditional risk factors alone.
Tuesday, June 25, 2013
Impaired Metabolism in Cystic Fibrosis Lung Epithelial Cells Revealed by Metabolic Analysis
Metabolon announces publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”.
Monday, October 25, 2010
Metabolon Awarded US Patent for Metabolic Biomarkers of Efficacy of PPAR Affecting Drugs
The USPTO awarded the patent to Metabolon on October 5, 2010.
Thursday, October 21, 2010
Metabolon Extends Biochemical Understanding of Alzheimers Disease
Publishes “Ablation of the Locus Coeruleus Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice” in the International Journal of Alzheimer Disease.
Thursday, October 14, 2010
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos